NASDAQ:MGX
Metagenomi Therapeutics, Inc.
Metagenomi Therapeutics, Inc.'s revenue fell 51.8% in fiscal 2025 to $25.2M while operating margin fell to −380.9%, its lowest in 3 years. Free cash flow was −$89.5M, −354.9% of revenue, and the diluted share count rose 12.8%.Summary generated from Metagenomi Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 5, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$25.2M
Revenue growth−51.8%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−380.9%
Net margin−348.5%
ROICn/a
Return on equity−44.7%
Debt / equityn/a
Free cash flow−$89.5M
FCF margin−354.9%
Share count change+12.8%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 45 | 52 | 25 |
| Operating income | −78 | −89 | −96 |
| Net income | −68 | −78 | −88 |
| Free cash flow | −101 | −112 | −89 |
Recent filings
- 8-KRegulation FD disclosure
Sep 22, 2026 - 4Insider transaction report
Sep 11, 2026 - 4Insider transaction report
Sep 10, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 10, 2026 - 8-KResults of operations and financial condition
Aug 10, 2026 - 8-KDirector or officer change
Jun 10, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 11, 2026 - 8-KResults of operations and financial condition
May 11, 2026